Table 1. Descriptive data of 100 patients diagnosed with spondyloarthritis included in the sample.
| Descriptive data | n=100 |
|---|---|
| SpA manifestation | |
| Ankylosing spondylitis | 53 |
| Psoriatic arthritis | 31 |
| Undifferentiated | 7 |
| IBD-related | 4 |
| Juvenile SpA | 2 |
| Reactive arthritis | 2 |
| Non radiographic SpA | 1 |
| Involvement | |
| Axial | 30 |
| Peripheral | 19 |
| Axial and peripheral | 51 |
| Sex | |
| Male | 53 |
| Female | 47 |
| Age, years | 16-73; mean 48.9±11.9 |
| Duration of disease, years | 1-30; median 7; IQR=3.2-12.0 |
| HLA-B27 positive | 42* |
| Medications | |
| Non-steroidal anti-inflammatory drugs | 43 |
| Methotrexate | 25 |
| Leflunomide | 51 |
| Anti-TNF-α | 51 |
| Etanercept | 17 |
| Adalimumab | 20 |
| Infliximab | 14 |
| BASDAI | 0-8, median 2.0 (IQR=1.0-3.4) |
| C-reactive protein, mg/dL | 0-43, median 6.0 (IQR=2.3-6.0) |
| ESR, mm | 1-100, median 16.5 (IQR=6.2-26.7) |
* Data available in 79 medical records only. IBD: inflammatory bowel disease; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; IQR: interquartile range; ESR: erythrocyte sedimentation rate; SpA: spondyloarthritis.